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E D I T O R I A L
Hemorrhagic stroke—Pathomechanisms of injury and 
therapeutic options
Each year, approximately 5.5 million people die due to a stroke in the 
world1 and this number could continue to rise with an aging popula‐
tion. The factors leading to a stroke are nonmodifiable or genetic and 
modifiable such as smoking, hypertension, diabetes mellitus, diet rich 
in fats and salt, and other environmental factors. The modifiable fac‐
tors serve as the key in preventing ischemic stroke and hemorrhagic 
stroke. Our understanding of the pathomechanisms of brain injury 
in hemorrhagic stroke (axial hemorrhage: intracerebral hemorrhage 
(ICH),	extra‐axial	hemorrhage:	subarachnoid	hemorrhage	(SAH),	in‐
traventricular hemorrhage (IVH), epidural hemorrhage, and subdu‐
ral hemorrhage), the less common subtype of stroke, has improved 
significantly during the past two decades. The bench side research 
in the field of cellular injury post‐ICH culminated in the first world 
ICH meeting at University of Michigan in 2005, under the guidance 
of Dr Julian T. Hoff. In the same vein, the current issue of CNSNT is 
a collection of various articles depicting the cellular/subcellular level 
of understanding of acute, subacute, and chronic cell injury in hem‐
orrhagic stroke and some related therapeutic options.
Cerebral hemorrhage leads to direct cerebral injury and then 
secondary injuries related to edema formation, inflammation, and 
a rise in intracranial pressure with consequent decline in cerebral 
perfusion pressure. Early brain injury following an episode of hem‐
orrhage is mediated partly by early erythrolysis, within the first 
24 hours.2 The hemoglobin burden then gets digested by heme oxy‐
genase, thus releasing the neurotoxin, iron. Iron‐mediated toxicity in 
the form of tissue edema, inflammation, and cellular death has been 
demonstrated in the rat and pig ICH models in great detail and has 
been reproduced by independent laboratories. The release of iron 
has effects on the blood‐brain barrier, endothelial‐pericyte interac‐
tion, veins, and glymphatics which mediate glial and axonal injury. 
Ischemic preconditioning is being investigated for its role in potential 
protection from delayed ischemic neurological deficit that results in 
20%‐30%	of	patients	with	SAH	due	to	vasospasm.	In	this	regard,	it	is	
interesting to note that hyperbaric oxygen pretreatment in rat ICH 
model reduces related injury by regulating polarization of microglial 
cells.3 This shows that there is room to investigate the oxygen equi‐
librium in the cellular and extracellular environment and how it can 
be modulated to offer neuroprotection in hemorrhagic stroke.
White	matter	injury	post‐ICH/SAH	is	an	important	pathological	
factor in patient outcomes. White matter injury can be secondary 
to the mechanical injury post‐hemorrhage, and it can also occur as 
a combination of injury to oligodendrocytes and damage to axons. 
Mediators like lipocalin‐2 have been demonstrated to be protec‐
tive	 to	hemorrhage‐mediated	white	matter	 injury	 in	a	mouse	SAH	
model.4 Unfortunately, white matter injury after ICH has not been 
well studied.5 In the current issue, Kang and Yao review the role of 
oligodendrocytes in ICH inducing white matter injury.6
Spontaneous or secondary IVH is a marker of poor prognosis for 
hemorrhagic stroke. Severe IVH, caused by extension from ICH or 
SAH,	leads	to	hydrocephalus	and	has	a	greater	risk	of	hemorrhage‐
associated morbidity. However, the mechanisms of brain hemor‐
rhage‐induced hydrocephalus are not well understood. In this special 
issue, Wan et al demonstrated that activation of epiplexus cells is 
associated	 with	 SAH‐	 and	 thrombin‐induced	 hydrocephalus.7 The 
effect of thrombin in hydrocephalus development may be through 
protease‐activated receptor‐1.8
In parallel, translation of the animal ICH model cellular under‐
standing of pathomechanisms to human subjects is gradually coming 
to fruition. This is coming in the form of magnetic resonance imaging 
(MRI) which can pick up susceptibility from iron in the hemoglobin 
and otherwise in the intracellular and extracellular environment. 
Investigators have demonstrated that just like in rat and pig ICH 
models9,10, tissue iron in the periphery of the hematoma can be 
picked up in the humans too11. The concentration of iron in the he‐
matoma is very high but currently there is no reliable measurement 
of iron concentration can be performed within it. On the other hand, 
in the periphery of the hematoma, such susceptibility compared to 
the tissue background can be picked up and quantified in the human 
subjects.11 The investigators at University of Michigan have also put 
forth the hypothesis that whether hemoglobin and its degradation 
products are within or without red blood cells, it dictates the type of 
signal on MRI.12 This phenomenon of T2* non‐hypointensity, related 
to early erythrolysis, demonstrated in the animal models, is being 
investigated in humans with MRI.13
Currently, no definite intervention has been shown to be ben‐
eficial for ICH, be it hematoma evacuation14,15 or iron chelation 
treatment such as deferoxamine.16 However, there is significant 
enthusiasm as MISTIE III has shown that patients who have greater 
than 75% of their ICH evacuated are clinically significantly better 
than those managed conservatively. In addition, iDEF has reported 
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better	 clinical	 results	 at	 6	months	 post‐ICH	 that	 approach	 signifi‐
cance for those patients receiving deferoxamine vs. placebo. In both 
of these treatments, preventing secondary injury to brain tissue is 
mediated favorably by the removal of deposited iron. Thus, a well‐
validated MRI‐based assessment of tissue iron concentration in the 
periphery of the hematoma will be very useful for monitoring treat‐
ment of hemorrhagic stroke patients with iron chelation agents (eg, 
deferoxamine).	The	evaluation	of	iron	concentration	post‐ICH/SAH	
treatment could serve as a marker not only of treatment but also of 
long‐term clinical outcome.
In summary, the future of hemorrhagic stroke research is looking 
bright and imaging‐based cellular brain injury pathways can be bet‐
ter	established	and	understood	on	MRI.	A	lot	more	work	is	needed	
to validate MRI‐based biomarkers and its correlation with functional 
outcome in patients with hemorrhagic stroke. The editors commend 
the authors for presenting a collection of articles at the cutting edge 
of understanding the underlying mechanisms of cerebral injury post‐
ICH	and	post‐SAH.
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